Patient characteristics
| . | PAdriaCEBO (%) . | PMitCEBO (%) . | χ2 . | P value . |
|---|---|---|---|---|
| No. of eligible patients | 243 | 230 | ||
| Male, no. (%) | 117 (48) | 118 (51) | 0.35 | .55 |
| Years of age, median (range) | 71 (60-84) | 71 (60-85) | .68* | |
| WHO PS, median (range) | 1 (0-4) | 1 (0-4) | .42 | |
| WHO PS, no. (%) | ||||
| 0 | 45 (20) | 59 (27) | ||
| 1 | 104 (46) | 86 (39) | ||
| 2 | 55 (24) | 45 (21) | ||
| 3 | 20 (9) | 23 (11) | ||
| 4 | 3 (1) | 5 (2) | ||
| “B” symptoms, no. (%) | 122 (54) | 105 (48) | 1.75 | .19 |
| Ann Arbor stage, no. (%) | ||||
| I | 15 (6) | 16 (7) | 0.48 | .49† |
| II | 80 (34) | 68 (30) | ||
| III | 49 (21) | 52 (23) | ||
| IV | 92 (39) | 93 (41) | ||
| Unknown, no. (%) | 7 (2) | 1 (< 1) | ||
| No. of extranodal sites, median (range) | 0 (0-3) | 0 (0-4) | .23* | |
| Extranodal sites, no. (%) | ||||
| 0 | 133 (55) | 115 (50) | ||
| 1 | 89 (37) | 85 (37) | ||
| 2 | 18 (7) | 26 (11) | ||
| 3 | 3 (1) | 3 (1) | ||
| 4 | 0 (0) | 1 (< 1) | ||
| Marrow involvement, no. | .33 | |||
| Negative | 186 | 182 | ||
| Positive | 41 | 30 | ||
| Unknown | 16 | 18 | ||
| LDH, median (range) | 548 (40-5382) | 466 (30-7759) | .14 | |
| Not performed, no. (%) | 75 (31) | 65 (28) | ||
| Age-adjusted IPI, no. (%) | ||||
| 0 | 45 (19) | 41 (18) | ||
| I | 93 (39) | 88 (38) | 0.27 | .97 |
| II | 72 (30) | 71 (31) | ||
| III | 27 (11) | 29 (13) |
| . | PAdriaCEBO (%) . | PMitCEBO (%) . | χ2 . | P value . |
|---|---|---|---|---|
| No. of eligible patients | 243 | 230 | ||
| Male, no. (%) | 117 (48) | 118 (51) | 0.35 | .55 |
| Years of age, median (range) | 71 (60-84) | 71 (60-85) | .68* | |
| WHO PS, median (range) | 1 (0-4) | 1 (0-4) | .42 | |
| WHO PS, no. (%) | ||||
| 0 | 45 (20) | 59 (27) | ||
| 1 | 104 (46) | 86 (39) | ||
| 2 | 55 (24) | 45 (21) | ||
| 3 | 20 (9) | 23 (11) | ||
| 4 | 3 (1) | 5 (2) | ||
| “B” symptoms, no. (%) | 122 (54) | 105 (48) | 1.75 | .19 |
| Ann Arbor stage, no. (%) | ||||
| I | 15 (6) | 16 (7) | 0.48 | .49† |
| II | 80 (34) | 68 (30) | ||
| III | 49 (21) | 52 (23) | ||
| IV | 92 (39) | 93 (41) | ||
| Unknown, no. (%) | 7 (2) | 1 (< 1) | ||
| No. of extranodal sites, median (range) | 0 (0-3) | 0 (0-4) | .23* | |
| Extranodal sites, no. (%) | ||||
| 0 | 133 (55) | 115 (50) | ||
| 1 | 89 (37) | 85 (37) | ||
| 2 | 18 (7) | 26 (11) | ||
| 3 | 3 (1) | 3 (1) | ||
| 4 | 0 (0) | 1 (< 1) | ||
| Marrow involvement, no. | .33 | |||
| Negative | 186 | 182 | ||
| Positive | 41 | 30 | ||
| Unknown | 16 | 18 | ||
| LDH, median (range) | 548 (40-5382) | 466 (30-7759) | .14 | |
| Not performed, no. (%) | 75 (31) | 65 (28) | ||
| Age-adjusted IPI, no. (%) | ||||
| 0 | 45 (19) | 41 (18) | ||
| I | 93 (39) | 88 (38) | 0.27 | .97 |
| II | 72 (30) | 71 (31) | ||
| III | 27 (11) | 29 (13) |